ENO2 and lung carcinoma: Notably, the sensitivity was 67.1% in detecting early-stage lung cancer, which was significantly higher than that of Cyfra21-1 (34.2%), NSE (6.5%), CA125 (5.8%), CEA (20.6%) and SCC (15.5%).